VGAIT for Chemotherapy-induced Peripheral Neuropathy
Video-Guided Acupuncture Imagery Treatment in Chemotherapy-induced Peripheral Neuropathy
1 other identifier
interventional
20
1 country
1
Brief Summary
Perform a feasibility study on imagined acupuncture treatment of Chemotherapy-induced peripheral neuropathy (CIPN)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 21, 2025
CompletedFirst Posted
Study publicly available on registry
September 17, 2025
CompletedStudy Start
First participant enrolled
January 6, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
February 10, 2026
February 1, 2026
11 months
July 21, 2025
February 6, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Feasibility related outcomes
Completion, satisfaction
8 week
Secondary Outcomes (6)
Patient Neurotoxicity Questionnaire (PNQ)
baseline, 8 week
Functional Assessment of Cancer Therapy-Neurotoxicity subscale (FACT-NTX)
baseline, 8 week
Brief Pain Inventory-short form (BPI-SF)
baseline, 8 week
European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (QLQ-C30) instrument
baseline, 8 week
MGH Acupuncture Sensation Scale (MASS)
after each intervention
- +1 more secondary outcomes
Study Arms (1)
VGAIT
EXPERIMENTALInterventions
Participants watch a video of acupuncture being applied to the body while simultaneously imagining that it is being administered to them
Eligibility Criteria
You may qualify if:
- at least 18 years of age
- have histologically confirmed stage I-III breast cancer,
- have completed adjuvant taxane-based chemotherapy (alone or in combination), ,
- have an Eastern Cooperative Oncology Group performance status of 0 or 1, and reported grade 1 or greater CIPN symptoms for more than 2 weeks as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
You may not qualify if:
- concurrent chemotherapy (there were no limitations on time from the last paclitaxel administration),
- having metastatic or recurrent disease,
- history of preexisting peripheral neuropathy prior to chemotherapy,
- uncontrolled seizure disorder,
- unstable cardiac disease or myocardial infarction within 6 months prior to study entry, being pregnant or nursing, or having used acupuncture for CIPN within 6 months prior to study entry.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Massachusetts General Hospital
Charlestown, Massachusetts, 02129, United States
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
July 21, 2025
First Posted
September 17, 2025
Study Start
January 6, 2026
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
February 10, 2026
Record last verified: 2026-02